+Compare
IMNM
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
88.29M

IMNM Immunome Forecast, Technical & Fundamental Analysis

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for IMNM with price predictions
08:00 PM EDT Sep 21, 2023

Momentum Indicator for IMNM turns negative, indicating new downward trend

IMNM saw its Momentum Indicator move below the 0 level on September 22, 2023. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 50 similar instances where the indicator turned negative. In of the 50 cases, the stock moved further down in the following days. The odds of a decline are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 29 cases where IMNM's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where IMNM declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

IMNM broke above its upper Bollinger Band on September 11, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for IMNM entered a downward trend on September 05, 2023. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IMNM's RSI Indicator exited the oversold zone, of 22 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for IMNM just turned positive on September 08, 2023. Looking at past instances where IMNM's MACD turned positive, the stock continued to rise in of 27 cases over the following month. The odds of a continued upward trend are .

IMNM moved above its 50-day moving average on September 21, 2023 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for IMNM crossed bullishly above the 50-day moving average on September 19, 2023. This indicates that the trend has shifted higher and could be considered a buy signal. In of 8 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IMNM advanced for three days, in of 150 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. IMNM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.434) is normal, around the industry mean (22.634). P/E Ratio (0.000) is within average values for comparable stocks, (131.508). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.085). Dividend Yield (0.000) settles around the average of (0.034) among similar stocks. P/S Ratio (13.245) is also within normal values, averaging (305.056).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IMNM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Novavax (NASDAQ:NVAX), Sorrento Therapeutics (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 402 to 410.28B. NVO holds the highest valuation in this group at 410.28B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -3%. For the same Industry, the average monthly price growth was 22%, and the average quarterly price growth was 34%. SKYED experienced the highest price growth at 81%, while SEEL experienced the biggest fall at -82%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -27%. For the same stocks of the Industry, the average monthly volume growth was 80% and the average quarterly volume growth was 85%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 87
Price Growth Rating: 69
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I. Advisor
published Earnings

IMNM is expected to report earnings to fall 63.04% to -17 cents per share on November 13

Immunome IMNM Stock Earnings Reports
Q3'23
Est.
$-0.17
Q2'23
Missed
by $0.30
Q1'23
Missed
by $0.93
Q4'22
Beat
by $0.04
Q3'22
Beat
by $0.01
The last earnings report on August 09 showed earnings per share of -46 cents, missing the estimate of -15 cents. With 2.45K shares outstanding, the current market capitalization sits at 88.29M.
A.I. Advisor
published General Information

General Information

Industry Biotechnology

Profile
Fundamentals
Details
Industry
N/A
Address
665 Stockton Drive
Phone
+1 610 321-3700
Employees
37
Web
https://www.immunome.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PEYUF9.230.02
+0.22%
Peyto Exploration & Development Corp
NSIDX11.86-0.04
-0.34%
Northern Small Cap Index
FAVFX31.34-0.12
-0.38%
Fidelity Advisor® Value A
OLVRX18.54-0.09
-0.48%
JPMorgan Large Cap Value R4
KBLB0.03N/A
-5.19%
Kraig Biocraft Laboratories

IMNM and

Correlation & Price change

A.I.dvisor indicates that over the last year, IMNM has been loosely correlated with MDGL. These tickers have moved in lockstep 33% of the time. This A.I.-generated data suggests there is some statistical probability that if IMNM jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IMNM
1D Price
Change %
IMNM100%
+0.21%
MDGL - IMNM
33%
Loosely correlated
-3.87%
BIOR - IMNM
33%
Poorly correlated
-2.74%
JSPR - IMNM
31%
Poorly correlated
+3.83%
ELOX - IMNM
30%
Poorly correlated
+3.29%
AXLA - IMNM
30%
Poorly correlated
+7.81%
More